老熟女另类,老熟女乱伦,老熟女乱婬一区二区,老熟女毛茸茸,老熟女毛茸茸黑森森,老熟女毛茸茸浓毛,老熟女网,老熟女网站。

CN / EN

News

Technoderma Medicines Advances TDM-180935 Atopic Dermatitis Clinical Program with Phase 2 Trial

Release time: 2024-04-30 Article source: 特科羅

CHENGDU, China, April 29, 2024 /PRNewswire/ -- Technoderma Medicines, Inc. ("the Company"), a clinical stage biopharmaceutical company, is pleased to report the Company has begun dosing patients in its Phase 2a clinical trial (NCT06363461) of topical TDM-180935 ointment. This clinical trial in the Atopic Dermatitis (AD) program includes 8 weeks dosing of two different active formulation strengths and placebo in a study entitled, "A Randomized, Vehicle-Controlled, Parallel Group Study of Topical TDM -180935 to Evaluate the Preliminary Efficacy, Safety, Tolerability, and Pharmacokinetics in Atopic Dermatitis Patients". It is a randomized, vehicle-controlled, parallel group comparison study with an open-label PK sub-study.  Objectives are to evaluate the safety and efficacy of topical TDM-180935 as well aspharmacokinetics. Seven U.S. clinical sites are currently participating in this study under an open IND with FDA.

Arthur P. Bertolino, MD, PhD, MBA, Chief Medical Officer at Technoderma Medicines commented, "We expect the current study to support Proof-of-Concept for TDM-180935 regarding efficacy and to guide choice of formulation strength(s) appropriate for continued development in our AD program. We are encouraged by the selective advantages that maybe provided by TDM-180935 as a potent JAK1/Tyk2 small molecule inhibitor."


About TDM-180935

TDM-180935 is a small molecule drug candidate being developed as a topical drug for treatment of Atopic Dermatitis. As a potent JAK1/Tyk2 small molecule inhibitor, it may offer significant advantages regarding efficacy and safety compared to existing topical treatments. Preclinical assessment of TDM-180935 has demonstrated efficacy in multiple models and that it is well-suited for topical administration. Functional cell assays demonstrate that TDM-180935 can effectively suppress both keratinocyte- and T cell-derived pathogenic pathways characteristic for Atopic Dermatitis. Testing in rats and minipigs demonstrated favorable toxicology and toxicokinetic profiles. Phase 1 clinical testing of topical TDM-180935 ointment has demonstrated excellent toleration and minimal systemic absorption.

About Atopic Dermatitis (AD)


Atopic Dermatitis (AD), also called eczema, is a chronic relapsing pruritic inflammatory skin disorder that typically affectsthe face,neck, hands and feet, and flexor aspects of extremities. Depending on disease stages (acute, subacute, chronic),typical AD lesions include redness, swelling,cracked or excoriated skin, scaly erythema or plaques with or without exudates,and lichenification, accompanied by severe pruritus and skind ryness. Repeated scratching triggers a self-perpetuatingitch-scratch cycle, which can have a significant impact on quality of life. The worldwide prevalence of AD is estimated to be15-20% in children and 1-3% in adults, and the incidence has increased by 2- to 3-fold during the past decades in industrializedcountries. The pathogenesis of AD involves four major aspects: disruption of skin barrier function,exposure to allergens,microbial infection, and dysregulated immune function. There are two  major risk factors of developing AD:one is the geneticdefect in the gene FLG encoding profilaggrin, the precursor of filaggrin protein present in the granular layer of the epidermiswhere it brings structural proteins together to create a strong barrier matrix; the other major risk factor is a family historyof atopic diseases such as food allergy, allergicrhinitis, and asthma.


About Technoderma Medicines


Technoderma Medicines, Inc. is a privately held clinical stage biopharmaceutical company located in Chengdu Tianfu BioPark,Sichuan, China. Its current core programs focus on development of innovative therapies for Androgenetic Alopecia,Atopic Dermatitis, Psoriasis and Lupus Erythematosus. Its "first-in- class" small molecule thyromimetic drug candidateTDM-105795 for Androgenetic Alopecia successfully completed Phase 2a clinical testing and is further advancing in development.Technoderma's novel JAK1/TYK2 inhibitor TDM-180935 for Atopic Dermatitis completed Phase 1 clinical testing with a favorablesafety profile and is now entering Ph2a testing. The pipeline targets dermatologic indications.


INVESTOR AND MEDIA CONTACT


Technoderma Medicines, Inc.

Zengquan Wang, PhD, CEO

[email protected]






主站蜘蛛池模板: 精品日本成人一区二区三区 | 国产李泌av在线播放 | 国产一区二区三区免费观看在线 | 欧美成人v片在线观看 | 免费的短视频app大全下载安装 | 91香蕉高清国产线观看免费 | 日韩a级黄片 | 国产91香蕉在线精品 | 91嫩草国产在线无码观看 | 亚洲精品国自产拍在线观看 | 国产日产精品毛片 | 国产精品无码视频影院 | 成人看片黄a免费看 | 东京热一区二区无码视频 | 中文字幕欧美第一页 | 国产真实强奷网站在线播放 | 91桃色永久免费福利版下载 | 亚洲无线观看国产高清 | 无码专区一v | 国产精品成人观看视 | 无码人妻一区二区三区精品视频 | 欧美亚洲综合久久偷偷人人 | 91综合精品国产丝袜长腿久久 | 又爽又黄又无遮挡的激情视频 | 91在线精品国产丝袜超清 | 欧美一级特黄aaaaaa在线看片 | 亚洲精品aa片在线观看国产 | 亚洲综合国产一区二区三区 | 亚洲精品国产成人99久久 | 91po国产在线精 | 欧美综合精品久久久久成人影院 | 日韩精品无码一区二区三区 | 免费在线观看91直播高清直播 | 欧美丰满熟妇xx猛交 | 18禁裸乳无遮挡啪啪无码免费 | 亚洲成a人片在线观看天堂无码 | 色欲人妻综合aaaaaaaa网 | 精品欧美一区二区在线观看欧美熟 | 国产在线精品一区二区高清不卡 | 日韩欧美一区二区三区在线观 | 国产乱人伦pp精品久久 |